Published in Semin Thromb Hemost on July 01, 1983
The antiphospholipid-thrombosis syndromes. Fact, fiction, confusion, and controversy. Am J Clin Pathol (1993) 1.93
Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost (1978) 1.22
Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res (1977) 1.13
An update on heparins at the beginning of the new millennium. Semin Thromb Hemost (2000) 0.95
A new two-stage functional assay for antithrombin-III (heparin cofactor): clinical and laboratory evaluation. Thromb Res (1976) 0.92
Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost (1985) 0.92
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am (1998) 0.91
Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. Ann Thorac Surg (1983) 0.85
Histiocytic medullary reticulosis in two Chinese women. West J Med (1974) 0.84
Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol (1980) 0.84
Hereditary and acquired thrombophilia. Part I. Preface. Semin Thromb Hemost (1999) 0.84
Fibrinolytic activity in acute myocardial infarction. Am J Clin Pathol (1972) 0.83
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol (1999) 0.83
In-vivo platelet inhibition by piracetam. Lancet (1979) 0.83
Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost (1976) 0.82
Bleeding times, platelet adhesion, and aspirin. Am J Clin Pathol (1976) 0.82
Laboratory modalities for assessing hemostasis during cardiopulmonary bypass. Semin Thromb Hemost (1976) 0.82
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost (1999) 0.81
Thrombotic thrombocytopenic purpura. An extended editorial. Semin Thromb Hemost (1979) 0.81
Anemia of malignancy. Hematol Oncol Clin North Am (1996) 0.81
Clinical use of intrapulmonary heparin. Semin Thromb Hemost (1985) 0.80
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemost (1982) 0.80
Antithrombin III and factor VIII in patients with neoplasms. Am J Clin Pathol (1978) 0.79
Clinical relevance of antithrombin III. Semin Thromb Hemost (1982) 0.79
Disseminated intravascular coagulation and related syndromes: etiology, pathophysiology, diagnosis, and management. Am J Hematol (1978) 0.79
Contaminants in heparins continue to be unfolded. Int Angiol (2008) 0.79
The clinical significance of fibrinogen degradation products. Semin Thromb Hemost (1982) 0.78
Deep vein thrombosis. Diagnosis and management. Med Clin North Am (1994) 0.77
Hemostatic defects induced by cardiopulmonary bypass. Vasc Surg (1976) 0.77
Prothrombin complex concentrate: use in controlling the hemorrhagic diathesis of chronic liver disease. Am J Dig Dis (1975) 0.77
Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost (1999) 0.76
Malaria in drug addicts. JAMA (1971) 0.76
Acquired defects of fibrinolysis associated with thrombosis. Semin Thromb Hemost (1999) 0.76
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clin Hemorheol Microcirc (2007) 0.76
Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost (1994) 0.75
Malaria transmission among narcotic addicts. A report of ten cases and review of the literature. Calif Med (1971) 0.75
Vascular disorders associated with thrombohemorrhagic phenomena. Semin Thromb Hemost (1979) 0.75
Evidence for a new activation phase clotting abnormality in a patient with the Hughes-Stoven syndrome. Beitr Pathol (1974) 0.75
Role of antithrombin III in clinical management of pulmonary embolization. Am J Med (1984) 0.75
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders. Clin Lab Med (1995) 0.75
Clinical implications of molecular markers in hemostasis and thrombosis. Semin Thromb Hemost (1984) 0.75
Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost (1999) 0.75
Discrepant AT-III and fibrinogen levels on the DuPont acaTM system. Am J Clin Pathol (1983) 0.75
Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. Ann N Y Acad Sci (1981) 0.75
Fibrinolytic potential in polycythemia rubra vera. Beitr Pathol (1974) 0.75
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. Semin Thromb Hemost (1984) 0.75
Laboratory diagnosis of antiphospholipid syndromes. Clin Lab Med (1995) 0.75
Antithrombins and coronary artery disease. Am J Clin Pathol (1984) 0.75
Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations. Semin Thromb Hemost (1999) 0.75
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Med Clin North Am (1998) 0.75
Adriamycin and fibrinolysis. Thromb Res (1976) 0.75
Fatal purpura fulminans following total cardiopulmonary bypass. J Cardiovasc Surg (Torino) (1974) 0.75
Fibrinolytic activity. Changes induced with oral contraceptives. Obstet Gynecol (1972) 0.75
The clinical relevance of plasminogen activator assays. Am J Clin Pathol (1989) 0.75
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem (1983) 0.75
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management. Clin Appl Thromb Hemost (1999) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Res (1975) 0.75
Needle malaria. N Engl J Med (1971) 0.75
Surgical hemostasis with a factor XL-containing concentrate. JAMA (1974) 0.75
Drug-induced alterations of hemostasis and fibrinolysis. Hematol Oncol Clin North Am (1992) 0.75
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung. Cancer Treat Rep (1976) 0.75
The effect of pinealectomy and environmental lighting on the gonadal, thyroid, and total body weight of female Long-Evans rats. Experientia (1969) 0.75
A comparative study of the DuPont antithrombin III and fibrinogen assay systems. Am J Clin Pathol (1985) 0.75
Fully automated antithrombin-III assays by synthetic substrate on the Multistat III. Am J Clin Pathol (1987) 0.75
Daunomycin and fibrinolysis. Thromb Res (1976) 0.75
Factor V: a simplified one-stage using a stabilized artificial substrate. Beitr Pathol (1973) 0.75
Current trends in the development of anticoagulant and antithrombotic drugs. Med Clin North Am (1994) 0.75
Disseminated intravascular coagulation: a clinical/laboratory study of 48 patients. Ann N Y Acad Sci (1981) 0.75
Biological antithrombin III levels. JAMA (1978) 0.75
Impact of automation on the quantitation of low molecular weight markers of hemostatic defects. Semin Thromb Hemost (1983) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Diath Haemorrh (1975) 0.75
Disseminated intravascular coagulation and blood component therapy. Transfusion (1976) 0.75
Alterations of hemostasis associated with cardiopulmonary bypass. Thromb Res (1976) 0.75